Patent · US Active

Diagnosis and therapy of hematological malignancies

US8524240B2 · kind B2 · utility

0Cited by

0References

4Claims

0Family size

Inventors

Djordje Atanackovic · Hamburg, DE
Tim Luetkens · Salt Lake City, US

Key dates

Filing date	Oct 25, 2010
Grant date	Sep 3, 2013
Priority date	—
Expiry date	Jun 22, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/53
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the field of diagnosis and therapy of hematological malignancies based on the tumor antigen FMR1NB (also called NY-SAR-35, Cancer/testis antigen 37 or Fragile X mental retardation 1 neighbor protein) and agents specifically targeting this antigen or cells expressing the same, e.g., antibodies. The inventors were able to prove that the molecule is expressed on the cell surface and thus represents a particularly advantageous target in cancer therapy and vaccination. Surprisingly, FMR1NB was found to be associated with hematological malignancies, e.g. acute myeloid leukemia (AML) or chronic myeloid leukemia (CML).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.